Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Multiple Sclerosis

  Free Subscription


Articles published in J Neurol Neurosurg Psychiatry

Retrieve available abstracts of 73 articles:
HTML format



Single Articles


    May 2020
  1. ABRAHAMYAN S, Eberspacher B, Hoshi MM, Aly L, et al
    Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 May 5. pii: jnnp-2020-322941.
    PubMed     Abstract available


    April 2020
  2. CHATAWAY J
    Distribution of plaques in the cerebrum in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 Apr 20. pii: jnnp-2019-322431.
    PubMed    


    March 2020
  3. ARNOLD DL, Banwell B, Bar-Or A, Ghezzi A, et al
    Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study.
    J Neurol Neurosurg Psychiatry. 2020 Mar 4. pii: jnnp-2019-322138.
    PubMed     Abstract available


  4. ESHAGHI A
    First approved treatment in children with multiple sclerosis slows brain atrophy.
    J Neurol Neurosurg Psychiatry. 2020 Mar 4. pii: jnnp-2019-322519.
    PubMed    


    February 2020
  5. GERALDES R, Jurynczyk M, Dos Passos G, Prichler A, et al
    Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 Feb 7. pii: jnnp-2019-322369.
    PubMed     Abstract available


    January 2020
  6. PROSPERINI L, Mancinelli C, Haggiag S, Cordioli C, et al
    Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2020 Jan 23. pii: jnnp-2019-322348.
    PubMed     Abstract available


    November 2019
  7. CHALMER TA, Buron M, Illes Z, Papp V, et al
    Clinically stable disease is associated with a lower risk of both income loss and disability pension for patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Nov 14. pii: jnnp-2019-321523.
    PubMed     Abstract available


    August 2019
  8. DEIVA K, Huppke P, Banwell B, Chitnis T, et al
    Consistent control of disease activity with fingolimod versus IFN beta-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS.
    J Neurol Neurosurg Psychiatry. 2019 Aug 29. pii: jnnp-2019-321124.
    PubMed     Abstract available


    July 2019
  9. COCCO E
    Getting older, getting worse: menopause as a turning-point for women living with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Jul 17. pii: jnnp-2019-321121.
    PubMed    


    June 2019
  10. SIMPSON S JR, Wang W, Otahal P, Blizzard L, et al
    Latitude continues to be significantly associated with the prevalence of multiple sclerosis: an updated meta-analysis.
    J Neurol Neurosurg Psychiatry. 2019 Jun 19. pii: jnnp-2018-320189.
    PubMed     Abstract available


  11. SIMPSON R, Simpson S, Ramparsad N, Lawrence M, et al
    Mindfulness-based interventions for mental well-being among people with multiple sclerosis: a systematic review and meta-analysis of randomised controlled trials.
    J Neurol Neurosurg Psychiatry. 2019 Jun 13. pii: jnnp-2018-320165.
    PubMed     Abstract available


  12. BARONCINI D, Annovazzi PO, De Rossi N, Mallucci G, et al
    Impact of natural menopause on multiple sclerosis: a multicentre study.
    J Neurol Neurosurg Psychiatry. 2019 Jun 12. pii: jnnp-2019-320587.
    PubMed     Abstract available


    May 2019
  13. MARTIN SJ, McGlasson S, Hunt D, Overell J, et al
    Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies.
    J Neurol Neurosurg Psychiatry. 2019 May 23. pii: jnnp-2018-319190.
    PubMed     Abstract available


  14. JOHN N, Carroll A, Brownlee WJ, Chataway J, et al
    Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 May 11. pii: jnnp-2019-320687.
    PubMed    


  15. TALLANTYRE EC, Major PC, Atherton MJ, Davies WA, et al
    How common is truly benign MS in a UK population?
    J Neurol Neurosurg Psychiatry. 2019;90:522-528.
    PubMed     Abstract available


    April 2019
  16. BROWNLEE WJ, Solanky B, Prados F, Yiannakas M, et al
    Cortical grey matter sodium accumulation is associated with disability and secondary progressive disease course in relapse-onset multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Apr 4. pii: jnnp-2018-319634.
    PubMed     Abstract available


    March 2019
  17. RAGONESE P
    Food of the gods for the treatment of multiple sclerosis related fatigue?
    J Neurol Neurosurg Psychiatry. 2019 Mar 4. pii: jnnp-2018-319926.
    PubMed    


  18. COE S, Cossington J, Collett J, Soundy A, et al
    A randomised double-blind placebo-controlled feasibility trial of flavonoid-rich cocoa for fatigue in people with relapsing and remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Mar 4. pii: jnnp-2018-319496.
    PubMed     Abstract available


  19. CRIELAARD L, Kavaliunas A, Ramanujam R, Olsson T, et al
    Factors associated with and long-term outcome of benign multiple sclerosis: a nationwide cohort study.
    J Neurol Neurosurg Psychiatry. 2019 Mar 1. pii: jnnp-2018-319913.
    PubMed     Abstract available


  20. GIOVANNONI G
    The unintended consequences of NICE.
    J Neurol Neurosurg Psychiatry. 2019;90:247-248.
    PubMed    


  21. SCARPAZZA C, Signori A, Prosperini L, Sormani MP, et al
    Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution.
    J Neurol Neurosurg Psychiatry. 2019;90:261-267.
    PubMed     Abstract available


    February 2019
  22. ZHANG Y, Zhou Y, van der Mei IAF, Simpson S, et al
    Lipid-related genetic polymorphisms significantly modulate the association between lipids and disability progression in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Feb 19. pii: jnnp-2018-319870.
    PubMed     Abstract available


    January 2019
  23. MANJALY ZM, Harrison NA, Critchley HD, Do CT, et al
    Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Jan 25. pii: jnnp-2018-320050.
    PubMed     Abstract available


  24. KALINCIK T, Kubala Havrdova E, Horakova D, Izquierdo G, et al
    Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Jan 13. pii: jnnp-2018-319831.
    PubMed     Abstract available


  25. FAREZ MF
    Food allergies and multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Jan 10. pii: jnnp-2018-319585.
    PubMed    


  26. ATKINS HL
    Another brick in the wall: further evidence supporting the role of haematopoietic stem cell transplantation in treating multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2019 Jan 10. pii: jnnp-2018-319715.
    PubMed    


  27. SORMANI MP, De Stefano N, Giovannoni G, Langdon D, et al
    Learning ability correlates with brain atrophy and disability progression in RRMS.
    J Neurol Neurosurg Psychiatry. 2019;90:38-43.
    PubMed     Abstract available


  28. WIJBURG MT, Warnke C, Barkhof F, Uitdehaag BMJ, et al
    Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort.
    J Neurol Neurosurg Psychiatry. 2019;90:44-46.
    PubMed     Abstract available


    December 2018
  29. FAKIH R, Diaz-Cruz C, Chua AS, Gonzalez C, et al
    Food allergies are associated with increased disease activity in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Dec 18. pii: jnnp-2018-319301.
    PubMed     Abstract available


  30. MOORE JJ, Massey JC, Ford CD, Khoo ML, et al
    Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Dec 11. pii: jnnp-2018-319446.
    PubMed     Abstract available


    November 2018
  31. CHARALAMBOUS T, Tur C, Prados F, Kanber B, et al
    Structural network disruption markers explain disability in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Nov 22. pii: jnnp-2018-318440.
    PubMed     Abstract available


    October 2018
  32. OCHI H
    Novel prognostic predictor of brain atrophy in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Oct 15. pii: jnnp-2018-319376.
    PubMed    


    September 2018
  33. PALACE J, Duddy M, Lawton M, Bregenzer T, et al
    Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme.
    J Neurol Neurosurg Psychiatry. 2018 Sep 21. pii: jnnp-2018-318360.
    PubMed     Abstract available


  34. KOUTSIS G, Breza M, Velonakis G, Tzartos J, et al
    X linked Charcot-Marie-Tooth disease and multiple sclerosis: emerging evidence for an association.
    J Neurol Neurosurg Psychiatry. 2018 Sep 8. pii: jnnp-2018-319014.
    PubMed     Abstract available


    July 2018
  35. JACOBS BM, Ammoscato F, Giovannoni G, Baker D, et al
    Cladribine: mechanisms and mysteries in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Jul 10. pii: jnnp-2017-317411.
    PubMed     Abstract available


  36. LANDI D, Ragonese P, Prosperini L, Nociti V, et al
    Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Jul 3. pii: jnnp-2018-318468.
    PubMed     Abstract available


    June 2018
  37. CHEN J, Taylor BV, Blizzard L, Simpson S Jr, et al
    Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
    J Neurol Neurosurg Psychiatry. 2018 Jun 19. pii: jnnp-2018-318228.
    PubMed     Abstract available


    May 2018
  38. TAYLOR BV
    Search for a prognostic biomarker in multiple sclerosis: a step in the right direction?
    J Neurol Neurosurg Psychiatry. 2018 May 15. pii: jnnp-2018-318326.
    PubMed    


  39. RATHBONE E, Durant L, Kinsella J, Parker AR, et al
    Cerebrospinal fluid immunoglobulin light chain ratios predict disease progression in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 May 9. pii: jnnp-2018-317947.
    PubMed     Abstract available


    April 2018
  40. CERQUEIRA JJ, Compston DAS, Geraldes R, Rosa MM, et al
    Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?
    J Neurol Neurosurg Psychiatry. 2018 Apr 4. pii: jnnp-2017-317509.
    PubMed    


    March 2018
  41. WIJNANDS JMA, Zhu F, Kingwell E, Fisk JD, et al
    Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
    J Neurol Neurosurg Psychiatry. 2018 Mar 30. pii: jnnp-2017-317493.
    PubMed     Abstract available


  42. POTTGEN J, Moss-Morris R, Wendebourg JM, Feddersen L, et al
    Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2018 Mar 16. pii: jnnp-2017-317463.
    PubMed     Abstract available


    December 2017
  43. PATTI F
    Standardised Frankincense extract: new possible therapeutic option for patients with relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Dec 23. pii: jnnp-2017-317380.
    PubMed    


  44. STURNER KH, Stellmann JP, Dorr J, Paul F, et al
    A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial).
    J Neurol Neurosurg Psychiatry. 2017 Dec 16. pii: jnnp-2017-317101.
    PubMed     Abstract available


  45. COCOZZA S, Petracca M, Mormina E, Buyukturkoglu K, et al
    Cerebellar lobule atrophy and disability in progressive MS.
    J Neurol Neurosurg Psychiatry. 2017;88:1065-1072.
    PubMed     Abstract available


    October 2017
  46. AZARY S, Schreiner T, Graves J, Waldman A, et al
    Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Oct 9. pii: jnnp-2017-315936.
    PubMed     Abstract available


  47. FITZGERALD K
    Diet and disease modification in multiple sclerosis: a nutritional epidemiology perspective.
    J Neurol Neurosurg Psychiatry. 2017 Oct 9. pii: jnnp-2017-316375.
    PubMed    


  48. MEIJER KA, Eijlers AJC, Geurts JJG, Schoonheim MM, et al
    Staging of cortical and deep grey matter functional connectivity changes in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Oct 6. pii: jnnp-2017-316329.
    PubMed     Abstract available


    September 2017
  49. GAJOFATTO A, Nourbakhsh B, Benedetti MD, Waubant E, et al
    Performance of 2010 McDonald criteria and 2016 MAGNIMS guidelines in the diagnosis of primary progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Sep 22. pii: jnnp-2017-316911.
    PubMed    


  50. PATERGNANI S, Castellazzi M, Bonora M, Marchi S, et al
    Autophagy and mitophagy elements are increased in body fluids of multiple sclerosis-affected individuals.
    J Neurol Neurosurg Psychiatry. 2017 Sep 2. pii: jnnp-2017-316234.
    PubMed    


    August 2017
  51. SPENCER JI, Bell JS, DeLuca GC
    Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier.
    J Neurol Neurosurg Psychiatry. 2017 Aug 31. pii: jnnp-2017-316011.
    PubMed     Abstract available


  52. CALABRESE M, Pitteri M, Farina G, Bajrami A, et al
    Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events.
    J Neurol Neurosurg Psychiatry. 2017 Aug 26. pii: jnnp-2017-316236.
    PubMed     Abstract available


  53. CLAFLIN SB, van der Mei IAF, Taylor BV
    Complementary and alternative treatments of multiple sclerosis: a review of the evidence from 2001 to 2016.
    J Neurol Neurosurg Psychiatry. 2017 Aug 2. pii: jnnp-2016-314490.
    PubMed     Abstract available


  54. KOCH-HENRIKSEN N, Laursen B, Stenager E, Magyari M, et al
    Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study.
    J Neurol Neurosurg Psychiatry. 2017;88:626-631.
    PubMed     Abstract available


  55. GRYTTEN N
    Survival in multiple sclerosis: things have changed.
    J Neurol Neurosurg Psychiatry. 2017;88:618.
    PubMed    


  56. LASCANO AM, Lalive PH, Hardmeier M, Fuhr P, et al
    Clinical evoked potentials in neurology: a review of techniques and indications.
    J Neurol Neurosurg Psychiatry. 2017;88:688-696.
    PubMed     Abstract available


    July 2017
  57. ZHOU Y, Graves JS, Simpson S Jr, Charlesworth JC, et al
    Genetic variation in the gene LRP2 increases relapse risk in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Jul 24. pii: jnnp-2017-315971.
    PubMed     Abstract available


  58. PREZIOSA P, Rocca MA, Mesaros S, Meani A, et al
    Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria.
    J Neurol Neurosurg Psychiatry. 2017 Jul 19. pii: jnnp-2017-315863.
    PubMed    


  59. EISELE P, Szabo K, Alonso A, Ong M, et al
    Lack of T1 hyperintensity in the dentate nucleus after 15 administrations of a macrocyclic contrast agent in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Jul 14. pii: jnnp-2017-316102.
    PubMed    


    May 2017
  60. TETTEY P, Simpson S, Taylor B, Ponsonby AL, et al
    An adverse lipid profile and increased levels of adiposity significantly predict clinical course after a first demyelinating event.
    J Neurol Neurosurg Psychiatry. 2017;88:395-401.
    PubMed     Abstract available


    April 2017
  61. RAGONESE P
    Mortality studies for multiple sclerosis: still a useful tool to analyse long-term outcome.
    J Neurol Neurosurg Psychiatry. 2017 Apr 28. pii: jnnp-2017-315591.
    PubMed    


  62. OKADA K, Kobata M, Sennari Y, Iwanaka Y, et al
    Levels of nitric oxide metabolites in cerebrospinal fluid correlate with cognitive impairment in early stage multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Apr 26. pii: jnnp-2017-315585.
    PubMed    


  63. LUNDE HB, Assmus J, Kjell-Morten M, Bo L, et al
    Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study.
    J Neurol Neurosurg Psychiatry. 2017 Apr 1. pii: jnnp-2016-315238.
    PubMed     Abstract available


  64. COMI G, De Stefano N, Freedman MS, Barkhof F, et al
    Subcutaneous interferon beta-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study.
    J Neurol Neurosurg Psychiatry. 2017;88:285-294.
    PubMed     Abstract available


    March 2017
  65. MURPHY R, O'Donoghue S, Counihan T, McDonald C, et al
    Neuropsychiatric syndromes of multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2017 Mar 11. pii: jnnp-2016-315367.
    PubMed     Abstract available


  66. ZALEWSKI NL, Morris PP, Weinshenker BG, Lucchinetti CF, et al
    Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders.
    J Neurol Neurosurg Psychiatry. 2017;88:218-225.
    PubMed     Abstract available


    February 2017
  67. JURYNCZYK M, Tackley G, Kong Y, Geraldes R, et al
    Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.
    J Neurol Neurosurg Psychiatry. 2017;88:132-136.
    PubMed     Abstract available


    December 2016
  68. ROCCA MA, Filippi M
    Modulation of cortical excitability to normalise brain function and improve cognition in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Dec 30. pii: jnnp-2016-315195.
    PubMed    


  69. HULST HE, Goldschmidt T, Nitsche MA, de Wit SJ, et al
    rTMS affects working memory performance, brain activation and functional connectivity in patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Dec 14. pii: jnnp-2016-314224.
    PubMed     Abstract available


    November 2016
  70. TAO C, Simpson S Jr, van der Mei I, Blizzard L, et al
    Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Nov 3. pii: jnnp-2016-314013.
    PubMed     Abstract available


    October 2016
  71. MOROSO A, Ruet A, Lamargue-Hamel D, Munsch F, et al
    Posterior lobules of the cerebellum and information processing speed at various stages of multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Oct 27. pii: jnnp-2016-313867.
    PubMed     Abstract available


    September 2016
  72. LIZAK N, Lugaresi A, Alroughani R, Lechner-Scott J, et al
    Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2016 Sep 28. pii: jnnp-2016-313976.
    PubMed     Abstract available


  73. KAWACHI I, Lassmann H
    Neurodegeneration in multiple sclerosis and neuromyelitis optica.
    J Neurol Neurosurg Psychiatry. 2016 Sep 26. pii: jnnp-2016-313300.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: